Funding for this research was provided by:
Deutsche Krebshilfe (70111764)
Faculty of Medicine, University of Freiburg (3091101336)
Deutsches Konsortium für Transnationale Krebsforschung (L661)
Received: 11 February 2018
Accepted: 5 November 2018
First Online: 19 November 2018
Ethics approval and consent to participate
: The study protocol has been approved by the German Federal Institute for Drugs and Medicine Devices and by the leading independent Ethics Committee of the University of Freiburg (EK 290/16). The study will be conducted in accordance with the ethical principles of the Declaration of Helsinki, the ICH-GCP Guidelines, the EU Clinical Trial Directive (2001/20/EG) and applicable regulatory requirements. Patient’s written consent to participate in this clinical trial is obtained prior to any study-specific procedures. The RIG-study has been registered in the ExternalRef removed registry (NCT02396628) and the Deutsches Register Klinische Studien (DRKS00007939).
: Not applicable.
: The authors declare that they have no competing interests.
: Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.